bioRxivBioengineeringPreprint
Electro-mechanical transfection for non-viral primary immune cell engineering
J. M. Sido, J. B. Hemphill, R. N. McCormack, R. D. Beighley, B. F. Grant, C. R. Buie, P. A. Garcia
Abstract
Non-viral approaches to transfection have emerged a viable option for gene transfer. Electro-mechanical transfection involving use of electric fields coupled with high fluid flow rates is a scalable strategy for cell therapy development and manufacturing. Unlike purely electric field-based or mechanical-based delivery methods, the combined effects result in delivery of genetic material at high efficiencies and low toxicity. This study focuses on delivery of reporter mRNA to show electro-mechanical transfection can be used successfully in human T cells. Rapid optimization of delivery to T cells was observed with efficiency over 90% and viability over 80%. Confirmation of optimized electro-mechanical transfection parameters was assessed in multiple use cases including a 50-fold scale up demonstration. Transcriptome and ontology analysis show that delivery, via electro-mechanical transfection, does not result in gene dysregulation. This study demonstrates that non-viral electro-mechanical transfection is an efficient and scalable method for cell and gene therapy engineering and development. One Sentence SummaryThis study demonstrates that non-viral electro-mechanical transfection is an efficient and scalable method for development of engineered cellular therapies.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Intracellular delivery of mRNA to human primary T cells with microfluidic vortex shedding
J. A. Jarrell, A. A. Twite, … R. S. Pawell·bioRxiv·Jan 5, 2019
- Viable and efficient electroporation-based genetic manipulation of unstimulated human T cells
P. Aksoy, B. A. Aksoy, … J. Hammerbacher·bioRxiv·Oct 20, 2019
- A Digital Microfluidic Platform for the Microscale Production of Functional Immune Cell Therapies
Samuel R. Little, Niloufar Rahbari, … Steve C. C. Shih·Analytical ChemistryPeer-reviewed·May 20, 2025
- Charge-Altering Releasable Transporters enable specific phenotypic manipulation of resting primary natural killer cells
A. J. Wilk, N. L. Benner, … C. A. Blish·bioRxiv·Feb 28, 2020
- Non-Viral Engineering of CAR-NK and CAR-T cells using the Tc Buster Transposon System™
E. J. Pomeroy, W. S. Lahr, … B. S. Moriarity·bioRxiv·Aug 2, 2021
- Genome editing human primary T cells with microfluidic vortex shedding & CRISPR Cas9
J. A. Jarrell, B. J. Sytsma, … R. S. Pawell·bioRxiv·Feb 26, 2020